

# **#FutureFresenius – Advancing Patient Care**

**dbAccess German Swiss Austrian Conference** June 21, 2023

### **Safe Harbor Statement**

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts.

Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.



# **1** Company Overview

- 2 Strategic Update
- 3 Business update Q1/23
- 4 Financial priorities & Outlook FY/23
- 5 Attachments

#### **Our mission for #FutureFresenius – Advancing Patient Care**



# Advancing Patient Care






### **A Global Leader in Healthcare Products and Services**




### **Global Trends offer Growth Opportunities for Fresenius**



Sources: <sup>1</sup> UN, Ageing and health (2021) <sup>2</sup> UBS, Longer Term Investments: EM healthcare (2018) <sup>3</sup> IDF Diabetes Atlas (2021) <sup>4</sup> AAM report (2021) <sup>5</sup> UBS, Longer Term Investments: Generics (2018)

## Fresenius Group: Global Revenue Base in Growing, Non-Cyclical Markets




Before special items 2018 excluding IFRS 16

# **Fresenius Group: Track Record of Healthy Organic Revenue Growth**



# **#FutureFresenius – Operating Companies and Investment Companies**



#### **Fresenius Group: Our Healthcare Portfolio**

# **Operating Companies**

Investment Companies

#### FRESENIUS KABI



Ownership: 100%

# Health products for critically and chronically ill patients

- Biopharmaceuticals
- Clinical Nutrition
- MedTech: Infusion and Nutrition Systems / Transfusion and Cell Technologies IV/Decag & Eluide
- IV Drugs & Fluids

#### Sales 2022: €7.9 bn

#### FRESENIUS HELIOS



Ownership: 100%

# Health services along the care continuum

- Acute care
- Outpatient services
- Occupational risk prevention
- Fertility services

Sales 2022: €11.7 bn

#### FRESENIUS MEDICAL CARE



Ownership: ~32%

#### **Dialysis services and products**

- Dialysis services
- Products for hemodialysis and peritoneal dialysis
- Critical care solutions
- Complementary assets to establish holistic treatment approach

#### Sales 2022: €19.4 bn





Ownership: 77%

#### **Project business and services**

- Post-acute care
- Project development and planning, turnkey construction
- Maintenance, technical and total operational management

Sales 2022: €2.4 bn

#### Fresenius Kabi: Comprehensive product portfolio for critically and chronically ill patients

- Balanced market reach with leading positions
- Vision 2026: "3+1" strategy focusing on three growth vectors Nutrition, MedTech and Biopharma; strengthening resilience in Pharma (IV Drugs Fluids) business
- Increasing global competitiveness and organizational effectiveness
- Broad industrial base with manufacturing excellence and unique channel access and customer proximity



Clinical nutrition



Medical devices /

transfusion technology



Biopharma





# **Market Dynamics** Growing healthcare spending in emerging markets +6.3% p.a. growth over the next decade Expected market growth of biosimilars 2021 to 2028 +27%average growth p.a. in the U.S. **Rising cost consciousness in** healthcare spending/significant savings from generics ~ US\$338 bn savings p.a. in the U.S.

# Fresenius Helios: Health services along the care continuum

- Market leader in size and quality driving for capital efficiency and value accretive growth
- ~6%<sup>1</sup> share in German acute care hospital market and ~12%<sup>1</sup> share in Spanish private hospital market
- Quality is key: defined quality targets, publication of medical treatment results, peer review processes
- Development of new business models to foster digitalization and benefit from trend towards outpatient treatments

#### Acute care



Outpatient

0	≥

Occupational risk prevention

Fertility services

<sup>1</sup> Based on sales




#### **Fresenius Medical Care: Dialysis services and products**

- The world's leading provider of dialysis products and services treating ~343,000 patients<sup>1</sup> in ~4,060 clinics<sup>1</sup>
- Advancing global transformation program FME25 to enable further sustainable profitable growth and execution on strategy



#### **Sales by Products and Services**



#### **Market Dynamics**

#### Increase in global demand

#### >1.6 million p.a.

patients worldwide will need continuous renal replacement therapy to treat acute kidney failure in 2030

#### Home dialysis


By 2025, the Company aims to perform **25%** of all treatments in the U.S. in a home setting

# Digitalization is driving new treatment models

Leverage ever larger data sets from **~53 million** dialysis treatments per year (2021) to further improve and personalize treatments

# **Fresenius Vamed: Project business and services**

- Manages hospital construction/expansion projects and provides services for healthcare facilities worldwide
- Offers project development, planning, turnkey construction, maintenance as well as technical management, and total operational management
- Strong track record: More than 1,000 projects in 98 countries completed
- Leading post-acute care provider in central Europe



# 


Post-acute care

Services

Projects

<del>4</del>7


# **Progressive dividend policy**




# **Fresenius SE: Fresenius Share & Shareholder Structure**




#### Shareholder structure by investors



#### Analyst recommendations







1 Company Overview

# <sup>2</sup> Strategic Update

- 3 Business update Q1/23
- 4 Financial priorities & Outlook FY/23
- 5 Attachments

#### **#FutureFresenius – ReSet delivered, now moving to ReVitalize**

# Structural simplification

# Sharpen focus

# Accelerate performance






#### **New F<sup>3</sup> - Fresenius Financial Framework**

		Frese	nius Group				
	Operating Com	panies		<b>Investment Companies</b> FSE expectation as major shareholder			
			FRESENIUS HELIOS 9 - 11%		US CARE	FRESENIUS 4 - 6%	
EBIT margin	14 - 17%	9 -			4%		
Organic	4 - 7%	3 - 5%					
revenue growth	4 7 /0	-					
revenue growth			CASH		DIVI	DEND	
		RUCTURE	Cash Cash Conver	sion Rate <sup>1</sup>		essive dividend	

#### Cost savings ramping up



### New management team formed



#### FSE / FMC to focus on performance



**Supportive and active long-term shareholder** to benefit from FMC value creation plan

Change from full consolidation to **at-equity consolidation of FMC** after conversion

No relevant impact on material financing arrangements at both FSE and FMC

**FSE one-time costs in low double-digit €m range**; negligible dissynergies from deconsolidation

#### Value upside retained, strategic optionality created

**Implementation expected Q3-4 2023** 

#### **F** FRESENIUS

#### **Clear benefits for FSE and FMC**

# **F** FRESENIUS



>

>

>

**Reduced complexity**, increased transparency

Sharpened management focus on operating companies

Enhanced strategic flexibility and **optionality** 





#### Simplified, entrepreneurial governance structure

Freed up management capacity to execute on turnaround



<

**Focused and faster** decision-making




 $\langle \rangle$ 


Additional **flexibility on** FMC's capital allocation

**FRESENIUS** 


# **#FutureFresenius – Operating Companies and Investment Companies**




# Fresenius Kabi – Accelerating our growth, driving performance



# **Fresenius Helios – Powerful set of care provision assets**



# Sharpen focus – Exit businesses in less attractive markets or where FSE not best owner





Develop business cells with **strong organic growth paths** 



Strengthen portfolio focus and capital allocation



Exit ~5+ cells with triple-digit-million € sales each, where Fresenius SE (FSE) is not the best owner



Support deleveraging

Details on portfolio exits over next 12-18 months

#### New, more rigorous F<sup>3</sup> – Fresenius Financial Framework





 $^{\rm 1}$  Cash Conversion Rate – defined as adjusted FCFbIT / EBIT before special items All figures before special items

### A clearer picture for 2024 and beyond



### Scale and impact across a broad range of therapies








- 1 Company Overview
- 2 Strategic Update RESET under way

# **3 Business update Q1/23**

- 4 Financial priorities & Outlook FY/23
- 5 Attachments

### Q1/23 – Good growth momentum



All P&L growth rates in constant currency (cc), before special items Net income attributable to shareholders of Fresenius SE & Co. KGaA <sup>1</sup> According to FY/23 guidance, excluding Provider Relief Fund (PRF) at Fresenius Medical Care

# Fresenius Kabi off to a good start to the year Q1/23 results



#### **QUARTERLY FINANCIALS** 15.9% 14.5% 2,000 **EBIT Margin** 14.3% <mark>11.6%،</mark> 13.5% Revenue 1,500 1,991 €m 1,847 1,000 Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 Revenue 1%2% 3% 7% 7% arowth org. EBIT €m 293 271 280 236 289 Before special items

# MAIN DEVELOPMENTS

- Strong organic revenue growth in all three growth vectors;
   Biopharmaceuticals with ongoing strong growth momentum
- Healthy growth in IV drugs & Fluids
- EBIT margin within margin band despite inflation
- Ongoing cost savings program as well as targeted pricing initiatives help offset pressure

# Fresenius Helios delivers solid Q1/23 Q1/23 results



**QUARTERLY FINANCIALS** 3,500 10.4% 10.4% 11.7% 10.1% **EBIT Margin** 3,000 7.8% Revenue 3,066 €m 2,500 2,931 2,000 Q1/22 Q2/22 Q3/22 Q4/22 Q1/23 Revenue 5% 6% 5% 5% 8% growth org. EBIT €m 306 303 222 354 311


# MAIN DEVELOPMENTS

- Healthy organic revenue growth mainly driven by Helios Spain including Latin America and Fertility
- EBIT margin well within structural margin band – continued ability to counter inflationary headwinds
- Higher energy costs in Germany mitigated by governmental support as well as achieved energy consumption savings of almost 20%
- Tariff negotiations Agreement with Verdi in Germany; ongoing in Spain; reflected in outlook

Before special items

# **Fresenius Vamed: Weak quarter, fixing underway** Q1/23 results





# MAIN DEVELOPMENTS

- Revenue growth driven by Technical Services business and European Project business
- Weak EBIT negatively impacted by legacy project portfolio, business initiations that did not materialize as planned as well as negative one-time effects mainly in the service business

# Major restructuring program initiated

- Streamlining organizational structures
- Stringent cost & efficiency measures
- Portfolio measures

# **Operating cash flow increased in Q1/23**

€m	Q1/23	Q1/22	Q1/23 LTM	Q1/22 LTM
OCF	175	101	4,272	4,527
% OCF Margin	1.7%	1.0%	10.3%	11.8%
Сарех	-352	-356	-1,773	-1,962
Capex in % of revenue	-3.4%	-3.6%	-4.3%	-5.1%
Acquisitions	-51	-92	-789	-829
Dividends	-53	-56	-887	-1,063
FCF	-281	-403	-823	-673

- Q1 structurally a weaker CF quarter with catch-up effects over the course of the year
- Q1 OCF increased by 73% over weak prior year quarter
- Vamed and Kabi with lower OCF
- Helios with healthy OCF above expectations
- LTM OCF Margin at 10.3%
- CAPEX below FY/23 expectation of around 5%




- 1 Company Overview
- 2 Strategic Update RESET under way
- 3 Business update Q1/23

# **4 Financial priorities & Outlook**

5 Attachments

#### **Clear financial priorities to accelerate performance and deliver value to shareholders**



#### Ambitious cost savings program announced – execution well on track




Cost savings program is fully on track to deliver on 2023 targets and beyond

~25% of full year 2023 EBIT savings realized during Q1 (~€130m)

FMC and Kabi as largest contributors to cost savings

Majority of one-time costs to occur in coming quarters, ~€50m of one-time costs in Q1

#### **Capital efficiency and returns to be improved over next quarters**



<sup>2</sup> At LTM

#### FY/23 – A year of structural progression

#### Persistent headwinds...



Reduced government support (excl. energy)

#### **Increased interest rates**

... but structural progression

Ramp-up of cost savings

**FMC deconsolidation** 

**>>>** 

**Further portfolio measures** 

Uptake of growth vectors

Increase to PY

## **Fresenius Group**

Revenue growth (organic) Low-to-mid-single-digit growth EBIT (cc growth)<sup>1</sup> including FMC: Broadly flat-to-high-single digit decline EBIT (cc growth) excluding FMC: Broadly flat-to-mid-single digit decline

#### **Operating Companies**

#### **Investment Companies**



 Mid-single-digit organic revenue growth

 EBIT margin around 14%; (structural EBIT margin band: 14 – 17%)



• Low-to-mid-single-digit revenue growth in cc

 Flat-to-high-single-digit operating income decline excl 2022 PRF<sup>1</sup>

- FRESENIUS HELIOS
- Mid-single-digit organic revenue growth
   Within


structural EBIT margin band of **9 – 11%** 



- Low-to-mid-single-digit
  - organic revenue growth
- Clearly below structural EBIT margin band of 4 – 6%


1 Adjusted EBIT excluding Provider Relief Funding (PRF); In 2022 Fresenius Medical Care received €277m (at current currency) Provider Relief Funding; No Provider Relief Funding support expected for 2023

## **FY/23 – Other financial KPIs**



## 2023 Targets for Environment, Social, Governance (ESG) KPIs

Targets aligned with Management Board Compensation Short-term Incentive (STI) 2023



42




## **Attachments**

#### Structural simplification – New structure expected to become effective in Q3 or Q4 2023



Key aspects & next steps

- Conversion into AG based on resolution of FMC extraordinary shareholder meeting
- 75% of FMC share capital present at EGM required to approve resolution
- Deconsolidation effective with registration of conversion into commercial register
- Implementation likely to take ~4 6 months post EGM



AGM = Annual general meeting EGM = Extraordinary general meeting

#### Illustrative financial implications from change of Fresenius Medical Care's legal form

	July 14	Registration in H2/23	After conversion
Current	Extraordinary General Meeting	Registration in commercial register	At equity accounting
<ul> <li>FMC fully consolidated</li> </ul>	<ul> <li>Application of IFRS 5</li> <li>FMC to be presented as separate line item in FSE's financial statement</li> <li>IFRS 5 adoption most likely leads to one-time P&amp;L effect due to revaluation of FMC at its market cap compared to the book value FSE holds</li> </ul>	<ul> <li>Effective date AG conversion and deconsolidation</li> <li>At equity accounting under IAS 28</li> <li>Further P&amp;L effect due to deconsolidation (mainly based on market capitalization of FMC and other adjustments, e.g. FX valuation)</li> </ul>	<ul> <li>Ongoing at equity accounting for FMG</li> <li>Separate line for equity result in P&amp;L (based on 32% share) impacted from results of necessary Purchase Price Allocation</li> <li>Separate line for at equity investment book value in Balance Sheet</li> </ul>



#### Impact of IFRS 5 adoption (in € billion):

	Fair Value of FMC (market capitalization), as of April 28, 2023	12.9
-	Carrying amount of FMC net assets less FMC NCIs, as of March 31, 2023	13.8
=	IFRS measurement effect for Fresenius Group $\rightarrow$ non-cash-effective, classified as special item	-0.9
	t/o allocated to noncontrolling interest	-0.6
	t/o attributable to shareholders of Fresenius SE	-0.3

Deconsolidation and Fair Value determination under IAS 28 could have further measurement effects; based on similar assumptions as at Step 1 (IFRS 5 adoption)

## Fresenius Kabi: Q1/23 Organic Revenue Growth by Product Group

€m	Q1/23	Δ YoY organic
MedTech	378	9%
Nutrition	602	8%
Biopharma	71	57%
<b>Growth Vectors</b> <sup>1</sup>	1,051	10%
<b>Pharma</b> (IV Drugs & Fluids)	940	3%
Total revenue	1,991	7%

<sup>1</sup> consists of MedTech, Nutrition, Biopharma

## Fresenius Kabi: Q1/23 EBIT(DA) development

€m	Q1/23	Δ YoY cc
<b>Total EBITDA</b>	<b>403</b>	<b>0%</b>
Margin	20.2%	-120 bps
Growth Vectors <sup>1</sup>	96	-17%
Margin	9.2%	-270 bps
Pharma (IV Drugs & Fluids)	197	4%
Margin	21.0%	+60 bps
Corporate	-4	37%
<b>Total EBIT</b>	<b>289</b>	<b>-4%</b>
Margin	14.5%	-140 bps

All figures before special items Margin growth at actual rates <sup>1</sup> consists of MedTech, Nutrition, Biopharma For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website <u>https://www.fresenius.com/results-center</u>.

#### **FRESENIUS**

## **Fresenius Helios: Q1/23 Key Financials**

€m	Q1/23	Δ YoY cc
Total revenue	3,066	<b>5%</b> <sup>1</sup>
Thereof Helios Germany	1,828	3%1
Thereof Helios Spain	1,170	8% <sup>1</sup>
Thereof Helios Fertility	66	18% <sup>1</sup>
<b>Total EBIT</b> Margin	<b>311</b> 10.1%	<b>2%</b> -30 bps
Thereof Helios Germany Margin	155 8.5%	1% -10 bps
Thereof Helios Spain Margin	157 13.4%	4% -60 bps
Thereof Helios Fertility Margin	4 6.1%	0% -90 bps
Thereof Corporate	-5	

<sup>1</sup> Organic growth

All figures before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

## **Fresenius Helios: Key Metrics**

	Q1/23	FY/22	Δ
Helios Germany			
Hospitals - Acute care hospitals	87 84	87 84	0% 0%
Beds - Acute care hospitals	<b>30,165</b> 29,599	30,352 29,786	-1% -1%
Admissions - patients treated in hospital - patients treated as outpatient	1,433,728 287,317 1,146,411	5,508,158 1,079,776 4,423,482	
Helios Spain (incl. Latin America)			
Hospitals	58	58	0%
Beds	8,267	8,259	0%
Admissions (including outpatients) - patients treated in hospital - patients treated as outpatient	<b>5,260,956</b> 300,546 4,960,410	18,853,264 1,067,410 17,785,854	

49

## **Fresenius Vamed: Q1/23 Key Financials**

€m	Q1/23	Δ YoY cc
Total revenue Thereof organic revenue	583	<b>13%</b> 13%
Project business	147	36%
Service business	436	7%
Total EBIT <sup>1</sup>	-27	
Order intake <sup>2</sup>	43	
Order backlog <sup>2</sup>	3,580	-3% <sup>3</sup>

<sup>1</sup> Before special items
 <sup>2</sup> Project business only
 <sup>3</sup> Versus December 31, 2022

## **Fresenius Group: Calculation of Noncontrolling Interests**

€m	Q1/23	Q1/22
Earnings before tax and noncontrolling interests	738	881
Taxes	-184	-200
Noncontrolling interests, thereof	-165	-218
Fresenius Medical Care net income not attributable to Fresenius (FY/22: ~68%)	-106	-137
Noncontrolling interest holders in Fresenius Medical Care	-47	-55
Noncontrolling interest holders in Fresenius Kabi (- $\in$ 14 m), Fresenius Helios (- $\in$ 5 m), Fresenius Vamed (- $\in$ 1 m) and due to Fresenius Vamed's 23% external ownership (+ $\in$ 8 m)	-12	-26
Net income attributable to Fresenius SE & Co. KGaA	389	463

Before special items

For a detailed overview of special items and adjustments please see the reconciliation tables provided on our website https://www.fresenius.com/results-center.

## **Fresenius Group: Cash Flow**

€m	Q1/23	Q1/23 LTM	LTM Margin	Δ ΥοΥ
Operating Cash Flow	175	4,272	10.3%	73%
Capex (net)	-352	-1,773	-4.3%	1%
Free Cash Flow	-177	2,499	6.0%	31%
(before acquisitions and dividends)				
Acquisitions (net)	-51	-789		
Dividends	-53	-887		
Free Cash Flow (after acquisitions and dividends)	-281	823	2.0%	30%

## **Fresenius Group: Reconciliation adjusted Free Cash Flow for CCR**

€m	Q1/23	Q1/22
Operating Cash Flow	175	101
Capex (net)	-352	-356
Free Cash Flow	-177	-255
(before acquisitions and dividends)		
Special items		
(net income before minorities)	+91	+82
Interests	+170	+119
(before special items)		
Taxes	+184	+200
(before special items)		
Adjusted Free Cash Flow for CCR	268	146

## **Cash Flow development Q1/23**

	Operating Cash Flow					С	Capex (net)			Free Cash Flow <sup>1</sup>				
€m		Q1/23	Q1/22	Q1/23 Margin	Q1/22 Margin	Q1/23	Q1/22	Q1/23 Margin	Q1/22 Margin	Q1/23	Q1/22	Q1/23 Margin	Q1/22 Margin	
<b>\$</b> \$	FRESENIUS KABI	21	133	1.1%	7.2%	-83	-94	-4.2%	-5.1%	-62	39	-3.1%	2.1%	
	FRESENIUS HELIOS	108	-136	3.5%	-4.6%	-95	-91	-3.1%	-3.1%	13	-227	0.4%	-7.7%	
	FRESENIUS MEDICAL CARE	143	159	3.0%	3.5%	-141	-160	-3.0%	-3.5%	2	-1	0.0%	0.0%	
V	FRESENIUS VAMED	-68	-45	-11.7%	-8.8%	-32	-9	-5.5%	-1.7%	-100	-54	-17.2%	-10.5%	
Со	rporate/Other	-29	-10	n.a.	n.a.	-1	-2	n.a.	n.a.	-30	-12	n.a.	n.a.	
	<b>RESENIUS</b> xcl. FMC <sup>2</sup>	32	-58	0.6%	-1.1%	-211	-196	-3.8%	-3.8%	-179	-254	-3.2%	-4.9%	
F F	RESENIUS	175	101	1.7%	1.0%	-352	-356	-3.4%	-3.6%	-177	-255	-1.7%	-2.6%	

<sup>1</sup> Before acquisitions and dividends <sup>2</sup> Including FMC dividends

## **Cash Flow development Q1/23 LTM**

	Operating Cash Flow					C	Capex (net)			Free Cash Flow <sup>1</sup>			
€m		Q1/23 LTM	Q1/22 LTM	Q1/23 Margin	Q1/22 Margin	Q1/23 LTM	Q1/22 LTM	Q1/23 Margin	Q1/22 Margin	Q1/23 LTM	Q1/22 LTM	Q1/23 Margin	Q1/22 Margin
<b>%</b>	FRESENIUS KABI	729	1,058	9.1%	14.5%	-507	-506	-6.3%	-6.9%	222	552	2.8%	7.6%
	FRESENIUS HELIOS	1,611	853	13.6%	7.6%	-558	-581	-4.7%	-5.2%	1,053	272	8.9%	2.4%
	FRESENIUS MEDICAL CARE	2,151	2,440	11.0%	13.6%	-668	-810	-3.4%	-4.5%	1,483	1,630	7.6%	9.1%
V	FRESENIUS VAMED	-67	150	-2.8%	6.4%	-4	-66	-0.1%	-2.8%	-71	84	-2.9%	3.6%
Со	rporate/Other	-152	26	n.a.	n.a.	-36	1	n.a.	n.a.	-188	27	n.a.	n.a.
	RESENIUS Excl. FMC <sup>2</sup>	2,248	2,213	10.3%	10.9%	-1,105	-1,152	-5.1%	-5.7%	1,143	1,061	5.2%	5.2%
F e	RESENIUS	4,272	4,527	10.3%	11.8%	-1,773	-1,962	-4.3%	-5.1%	2,499	2,565	6.0%	6.7%

<sup>1</sup> Before acquisitions and dividends <sup>2</sup> Including FMC dividends

## **Revenue by Business Segment – FX, Acquisitions/Divestitures Effects Q1/23**

€m	Q1/23	Q1/22	Growth at actual rates	Currency translation effects	Growth at constant rates	Organic growth	Acquisi- tions	Divesti- tures/ Others
Fresenius Kabi	1,991	1,847	8%	0%	8%	7%	2%	-1%
Fresenius Helios	3,066	2,931	5%	0%	5%	5%	0%	0%
Fresenius Medical Care	4,704	4,548	3%	1%	2%	2%	0%	0%
Fresenius Vamed	583	513	14%	1%	13%	13%	0%	0%
Total	10,225	9,720	5%	0%	5%	5%	1%	-1%

#### **Financial Calendar / Contact**

Financial Calendar		Social Media		
02 August 2023 Results Q2/23		Follow Fresenius Investor Relations & Sustainability on LinkedIn:		
02 November 2023	Results Q3/23			
Please note that these dates could	be subject to change.			

#### Contact

Investor Relations & Sustainability Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: ir-fre@fresenius.com For further information and current news: www.fresenius.com



www.twitter.com/fresenius\_ir

www.linkedin.com/company/fresenius-investor-relations



# **#FutureFresenius**